WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 13% more annual revenue ($28.43B vs $25.12B). SYK leads profitability with a 12.9% profit margin vs 4.1%. MDLN trades at a lower P/E of 29.9x. SYK earns a higher WallStSmart Score of 65/100 (C+).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.67

$24.25 discount

UndervaluedFair: $66.92Overvalued
SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

MDLN is growing revenue faster at 14.8% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (65/100 vs 52/100) and 11.4% revenue growth. MDLN offers better value entry with a 32.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?